Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Revenues, Losses Down in Last Quarter Prior to Merger with Genesoft

NEW YORK, March 5 (GenomeWeb News) - Genome Therapeutics reported decreased revenues and losses for the fourth quarter of 2003 today, the last quarter prior to its merger with Genesoft Pharmaceuticals, which was completed last month.


The company recorded $1.7 million in revenues, down from $5.8 million during the same period last year.


R&D expenses reached $4.6 million, down from $7.1 million year-over-year.


Genome Therapeutics reported a net loss of $1.3 million, or $.04 per share, down from $8.8 million, or $.38 per share, during the year-ago period.


As of Dec. 31, the company had $29 million in cash, cash equivalents, and marketable securities. This does not include $81 million in net proceeds Genome Therapeutics raised last month in conjunction with its merger with Genesoft.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.